HHLR Advisors’s Ambrx Biopharma Inc AMAM Stock Holding History

HHLR Advisors’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-31,735	Closed	-$365K	–	61
2023 Q3	$365K	Buy	+31,735	New	+$432K	0.01%	57

Other funds holding AMAM

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HHLR Advisors's AMAM Position: Q4 2023 in Review

HHLR Advisors sold out of Ambrx Biopharma Inc (AMAM) in Q4 2023, closing a stake of 31,735 shares — an estimated $365K sold.

HHLR Advisors first reported a position in AMAM in Q3 2023 and held it in 1 quarter. The position peaked at $365K in Q3 2023. 68 funds tracked by Wall St. Rank hold AMAM as of Q4 2023.

HHLR Advisors reported no remaining Ambrx Biopharma Inc position as of Q4 2023 after selling out during the quarter.
HHLR Advisors sold 31,735 Ambrx Biopharma Inc shares in Q4 2023, an estimated $365K.
HHLR Advisors first reported a position in Ambrx Biopharma Inc in Q3 2023 and held it in 1 quarter.
HHLR Advisors's Ambrx Biopharma Inc position peaked at $365K in Q3 2023.
68 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q4 2023.

Based on HHLR Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.